• Ajay K Nooka, Jonathan L Kaufman, Craig C Hofmeister, Nisha S Joseph, Thomas L Heffner, Vikas A Gupta, Harold C Sullivan, Andrew S Neish, Madhav V Dhodapkar, and Sagar Lonial.
• Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
• Cancer. 2019 Jul 15; 125 (14): 2364-2382.

AbstractThe development of effective monoclonal antibodies for the treatment of myeloma has been a long journey of clinical and drug development. Identification of the right target antigen was a critical part of the process. CD38 as a target has been considered for some time, but clinically, daratumumab, a CD38 monoclonal antibody, was the first to be tested, and it has delivered the best clinical responses as a single agent to date. Its proven safety and efficacy in combination with other antimyeloma agents have led to several US Food and Drug Administration approvals for treating myeloma. Furthermore, the results of early trials in the induction therapy setting have demonstrated a beneficial role when it is added to the existing induction regimens. This review summarizes the importance of CD38 as a target and examines the clinical development of the CD38 monoclonal antibody daratumumab and its clinical significance in combination regimens in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma.© 2019 American Cancer Society.

36 keywords...

hide…